2024-12-18 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the analyzed period, MRK's cumulative return (64.42%) significantly underperformed the S&P 500 (VOO) which had a cumulative return of 121.78%. The difference is -57.4%, placing it in the 5.6th percentile of its historical performance relative to the S&P 500.  This indicates consistent underperformance compared to the broader market. The provided alpha consistently shows a negative value (-0.1), suggesting underperformance relative to the market benchmark. Beta values fluctuate, but generally suggest higher volatility than the market.


**2. Recent Price Movement:**

* **Closing Price:** $100.06
* **Last Market Price:** $100.07
* **5-Day Moving Average:** $100.81
* **20-Day Moving Average:** $100.77
* **60-Day Moving Average:** $104.86

The price is currently trading below all three moving averages, suggesting a bearish short-term trend.

**3. Technical Indicators & Expected Return:**

* **RSI (46.9):** Suggests the stock is approaching oversold territory, but not yet definitively so.
* **PPO (0.16):** A positive value indicates bullish momentum, although relatively weak.
* **20-Day Relative Divergence (-6.2):** Shows a recent decline in relative strength.
* **Expected Return (0.0%):**  The model predicts no significant outperformance relative to the S&P 500 over the long term (2+ years) based on the provided data.  This aligns with the historical underperformance.  A long-term buy-and-hold strategy would need to consider the risk of continued underperformance against the market.  The Last-market value of $100.07 doesn't significantly deviate from the closing price to suggest any rapid price movement.


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue:

* **Revenue:** Revenue shows a generally upward trend, although the growth rate isn't consistent quarter-over-quarter.  There's a slight dip in Q4 2023, followed by modest growth in subsequent quarters.
* **EPS:** EPS fluctuates significantly, with the highest value in Q2 2024 ($2.15) and lower values in other quarters.  There is no information on whether these figures met or exceeded expectations, making a comprehensive evaluation impossible with the provided data alone.
* **Quarterly Comparison:**  Comparing sequential quarters reveals inconsistencies in both revenue and EPS, hindering clear trend identification.  More detailed analysis would require more contextual data.  Note the duplicate entry for 2024-11-06.

**5. Financial Information Analysis:**

* **Revenue and Profitability:**  Revenue shows consistent growth for the past year, although the rate varies. Profit margins are generally high but show some fluctuation, decreasing in Q4 2023 before recovering.
* **Capital and Profitability:** Equity has generally increased, but ROE shows significant volatility, including a negative value in Q4 2023.  This suggests potential underlying issues that would require further investigation.

**6. News and Recent Issues:**

No recent (within the last two days) earnings news or analyst opinions are provided.  Information on the recent market outlook is also absent. This section lacks critical information needed for a complete analysis.

**7. Overall Analysis:**

Merck (MRK) has demonstrated consistent underperformance relative to the S&P 500 over the analyzed period.  While revenue shows a general upward trend, EPS and ROE exhibit volatility. Technical indicators suggest a potential for short-term bearish movement but are not definitively bearish. The absence of recent news and a lack of context regarding earnings expectations limit a thorough assessment. The significant fluctuations in profitability metrics (ROE) necessitate further investigation into the underlying causes.  Long-term investors should carefully consider the history of underperformance relative to the market before making any investment decisions.  A more comprehensive analysis would require additional data, particularly regarding analyst expectations and recent market events.

**8. Disclaimer:** This analysis is based solely on the provided data.  It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough independent research and consult with a financial advisor before making any investment.
